KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Payables (2018 - 2025)

Vir Biotechnology's Payables history spans 8 years, with the latest figure at $9.8 million for Q4 2025.

  • On a quarterly basis, Payables rose 92.93% to $9.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.8 million, a 92.93% increase, with the full-year FY2025 number at $9.8 million, up 92.93% from a year prior.
  • Payables hit $9.8 million in Q4 2025 for Vir Biotechnology, up from $6.8 million in the prior quarter.
  • Over the last five years, Payables for VIR hit a ceiling of $12.4 million in Q2 2023 and a floor of $2.7 million in Q3 2022.
  • Historically, Payables has averaged $7.4 million across 5 years, with a median of $6.7 million in 2021.
  • Biggest five-year swings in Payables: tumbled 80.28% in 2021 and later surged 196.0% in 2022.
  • Tracing VIR's Payables over 5 years: stood at $6.5 million in 2021, then dropped by 1.52% to $6.4 million in 2022, then dropped by 1.37% to $6.3 million in 2023, then decreased by 19.78% to $5.1 million in 2024, then skyrocketed by 92.93% to $9.8 million in 2025.
  • Business Quant data shows Payables for VIR at $9.8 million in Q4 2025, $6.8 million in Q3 2025, and $12.2 million in Q2 2025.